Narcobarbital

Narcobarbital
Clinical data
ATC code	N01AG01 (WHO) ;
Identifiers
	IUPAC name 5-(2-bromoprop-2-en-1-yl)-5-isopropyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione;
CAS Number	125-55-3 ;
PubChem CID	18735;
ChemSpider	17691 ;
UNII	A77U8G9H84;
KEGG	C17722 ;
ChEMBL	ChEMBL92963 ;
CompTox Dashboard (EPA)	DTXSID30871609 ;
Chemical and physical data
Formula	C11H15BrN2O3
Molar mass	303.156 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(C(=O)NC(=O)C1(CC(\Br)=C)C(C)C)C;
	InChI InChI=1S/C11H15BrN2O3/c1-6(2)11(5-7(3)12)8(15)13-10(17)14(4)9(11)16/h6H,3,5H2,1-2,4H3,(H,13,15,17) ; Key:WGMASVSHOSNKMF-UHFFFAOYSA-N ;
	(verify)

Narcobarbital (Pronarcon) is a barbiturate derivative developed in 1932 by Carl Heinrich Friedrich Boedecker and Heinrich Gruber Schoneberg, assignors to the firm J. D. Riedel-E. de Haën AG, Berlin, Germany. Later, in 1937, may, was patented in United States.^[1] It is an N-[[methylated] derivative of propallylonal and has similar sedative effects. It is still used in veterinary medicine for inducing surgical anaesthesia.^[2]